Rising Prevalence Of Esophageal Diseases Drives Growth In The Gastroesophageal Reflux Disease (GERD) Market: Strategic Insights Driving Gastroesophageal Reflux Disease (GERD) Market Momentum in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Gastroesophageal Reflux Disease (GERD) Market Size By 2025?
The market encompassing gastroesophageal reflux disease (GERD) has experienced a slight expansion lately, projected to advance from its 2024 valuation of $5.25 billion to $5.33 billion by 2025, reflecting a compound annual growth rate of 1.6%; this upward trajectory during the past period is linked to shifts in lifestyle and nutrition, the rising prevalence of obesity, increased knowledge regarding GERD therapies, global expansion within the pharmaceutical sector, and capital poured into developing GERD treatments.

How Big Is the Gastroesophageal Reflux Disease (GERD) Market Size Expected to Grow by 2029?
Anticipation surrounds the gastroesophageal reflux disease (GERD) market, projecting a consistent upward trajectory in the forthcoming years, culminating in a valuation of $5.95 billion by 2029, sustained by a compound annual growth rate (CAGR) of 2.8%. This expansion is fundamentally driven by several factors, including the demographic shift toward an older population, escalating expenditure on healthcare, the advent of novel biomarkers, an increasing volume of GERD screening initiatives, the heightened incidence of heartburn symptoms, and a greater need for medical apparatus. Key developments shaping the market's future involve progress in diagnostic methodologies, surgical techniques, the creation of specialized therapeutic agents, and the wider implementation of remote healthcare consultations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-gerd-global-market-report

Which Key Market Drivers Powering Gastroesophageal Reflux Disease (GERD) Market Expansion and Growth?
Anticipated expansion in the occurrence of conditions affecting the esophagus is projected to boost the trajectory of the gastroesophageal reflux disease (GERD) market in the future. These esophageal ailments constitute health issues impacting the esophagus, which functions as a muscular conduit linking the oral cavity to the stomach. Therapeutic interventions for esophageal disorders strive to mitigate discomfort, enhance the standard of living, and avert secondary issues, consequently fostering superior general health and comfort for those suffering from gastroesophageal reflux disease. To illustrate this escalating concern, data from the American Cancer Society, a professional body located in the US, indicated that around 21,560 new instances of esophageal cancer are identified annually across the United States as of January 2023, resulting in 16,120 fatalities attributed to this cancer. Consequently, the increasing incidence of esophageal diseases acts as a catalyst for the advancement of the gastroesophageal reflux disease (GERD) market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12917&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Gastroesophageal Reflux Disease (GERD) Market?
Leading entities within the gastroesophageal reflux disease (GERD) sector are concentrating efforts on rolling out novel therapeutic devices for GERD to solidify their market standing. As an illustration, in April of 2023, the American medical technology firm Laborie Medical Technologies introduced the alpHaONE, a recently developed wireless pH-capsule diagnostic system explicitly intended for identifying gastroesophageal reflux disease. This monitoring apparatus is capable of gathering data spanning as long as 96 hours, and it boasts a smaller footprint alongside tactile, expanded controls and a reliable mechanism for capsule deployment. Enhancement of the operator experience is achieved through a software package that incorporates a digital guidance module and symptom recording buttons that users can tailor to their specific needs.

What Are the Emerging Segments in the Gastroesophageal Reflux Disease (GERD) Market?
The gastroesophageal reflux disease (gerd)market covered in this report is segmented -

1) By Drug Type: Antacids; Proton Pump Inhibitors; H2 Receptor Blocker; Pro Kinetic Agents; Dopamine Receptor Antagonist; EndoCinch; Stretta; EsophyX; Transoral Incisionless Fundoplication (TIF)
2) By Procedure: Invasive; Minimally Invasive
3) By End-Users: Hospital; Homecare; Specialty Clinics

Subsegments:
1) By Antacids: Calcium Carbonate; Magnesium Hydroxide; Aluminum Hydroxide
2) By Proton Pump Inhibitors: Omeprazole; Esomeprazole; Lansoprazole; Pantoprazole; Rabeprazole
3) By H2 Receptor Blockers: Ranitidine; Famotidine; Nizatidine; Cimetidine
4) By Prokinetic Agents: Metoclopramide; Domperidone
5) By Dopamine Receptor Antagonists: Prochlorperazine; Droperidol
6) By EndoCinch: Endoscopic Suturing Systems
7) By Stretta: Radiofrequency Ablation Systems
8) By EsophyX: Transoral Fundoplication Systems
9) By Transoral Incisionless Fundoplication (TIF): TIF Devices And Systems

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12917&type=smp

Who Are the Global Leaders in the Gastroesophageal Reflux Disease (GERD) Market?
Major companies operating in the gastroesophageal reflux disease (GERD) market are GlaxoSmithKline PLC, SRS Life Sciences, Johnson & Johnson Services Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Reckitt Benckiser Group PLC, Eisai Co. Ltd., Pfizer Inc., Medtronic PLC, Teva Pharmaceuticals, HK inno.N Corporation, Sebela Pharmaceuticals, Mylan N.V., Bausch Health Companies Inc., Johnson & Johnson MedTech, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., Almirall S.A., HK inno.N Corporation, SRS Life Sciences Pte. Ltd.

Which are the Top Profitable Regional Markets for the Gastroesophageal Reflux Disease (GERD) Industry?
North America was the largest region in the gastroesophageal reflux disease (GERD) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastroesophageal reflux disease (GERD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12917

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.